关于公司
Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.
US
未知
未知
未验证公司
业务透明度
- 未验证公司信息
- 向他们的客户询问评论
- 没有回复负面评论